IMM Chart, page-32

Alright people, have a look at this
https://www.fiercepharma.com/marketing/merck-scraps-keytruda-lung-cancer-trial-adding-bristol-myers-yervoy-what-about-opdivo

Merck decided to stop adding Bristol Myers’ CTLA-4 inhibitor Yervoy to Keytruda in a phase 3 trial among newly diagnosed patients with metastatic NSCLC whose tumors express PD-L1...........

The termination came after an independent data monitoring committee found the combo was not at all better than solo Keytruda at staving off cancer progression or extending patients’ lives. Instead, more severe side effects cropped up in the dual-therapy arm than in the monotherapy group, to the point where the expert panel is asking patients to stop taking Yervoy or placebo............

So in case you don't know what's CTLA-4, let's say that's just another molecle in our body that has similar potential like LAG3, as a drug target to treat tumor in those immuno-checkpoint path. In layman's word, this CTLA4/Keytruda combo has found not good for NSCLC cases, even in PD-1 expressing patient. Not even think about apply CTLA4 inhibitor on PD-1 low or negative patients like our TACTI study then.

Ahh, you now know what I am gonna say next.......
Then the duty for taking good care of NSCLC patients are left onto LAG3 inhibitor like EFTI from Immutep or the one from BMS.
Just think about the TACTI-002 study, excellent safty profile with combo treatment, comparing to the sh!tty sounding one above?
Almost doubled the overall responding rate in high PD-1 expressing group comparing to Keytruda mono therapy, of which Keytruda mono treatment could not achieve in the KN024 study. Plus with good responding rate on all PD-1 level groups.

The new added in data this round, with the PD-1 treatment numbness patients, still shows 34% of disease control rate, however, only achieved 4.4% overall responding rate by calculation on paper. I have been finding the reason(s) responsible for the price action for the last 2 days and now I am inclined to attribute to this one, the lowish responding rate.

Though, from scientific perspective/ clinical point of view/ ethically, I think this bit is the best data within that poster. If you think about that group of paitents, with the current human medicine, nothing is working on them, and this EFTI/Keytruda combo has keep more than half of the patients alive for 12months so far. Some of those paitents get to see their new born child/grandchild, or attend their graduation, their wedding, etc..... To me, the responding rate speaking to the cure of the disease is not so important, but the survival rate is a lot more important if you ask them.

From the market action point of view, I would say the big funds take this as an opportunity, when the large public thinks this is not so good, and also when the Part B stage 1 of the study is not yet up to showing the overall survival rate and stage 2 is not even opened, they just take control of the price. Such observation has been seen more than once in my previous/current other holdings, with a strong share price suppression during the price up stage. Eventually, price up is non-stoppable with the current scientific fundemental.

So people, I would not put the words 'just relax now and wait', i'd say think of how you gonna deal with your high adrenoline level when price jump quickly, as things are happening.